$36.5M Capital Infusion Secured by Citius Oncology to Accelerate LYMPHIR Launch
CTOR sits 98% above its 52-week low of $0.491 on light trading volume (0.1× avg).
Summary
Citius Oncology, Inc. (CTOR) has secured up to $36.5 million in new capital, a critical development for the company. This financing package includes a senior secured term loan facility of up to $25 million from Avenue Capital Group, with an initial $10 million funded immediately, and approximately $11.5 million from the immediate exercise of outstanding warrants by a single institutional investor. This capital directly addresses the company's severe liquidity issues, as highlighted by its last 10-Q which expressed substantial doubt about its ability to continue as a going concern with cash expected to last only until May 2026, and its recent Nasdaq delisting notice. The funding is earmarked to accelerate the commercialization of its FDA-approved drug, LYMPHIR, following its recent initial shipment to Europe. While providing essential operational runway, the deal involves significant potential dilution through new warrants and conversion rights. Traders will closely watch the company's commercial execution and its ability to meet revenue milestones to unlock the additional debt tranches.
At the time of this announcement, CTOR was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.5M. The 52-week trading range was $0.49 to $6.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.